Biropepimut-S - Gliknik

Drug Profile

Biropepimut-S - Gliknik

Alternative Names: GL-0817; MAGE-A3 vaccine

Latest Information Update: 20 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mayo Clinic; University of Maryland, Baltimore
  • Developer Gliknik; University of Pennsylvania
  • Class Cancer vaccines; Peptides
  • Mechanism of Action Immunostimulants; MAGEA-3-protein-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Head and neck cancer; Squamous cell cancer
  • No development reported Multiple myeloma

Most Recent Events

  • 01 Mar 2017 Phase-II clinical trials in Squamous cell cancer (Combination therapy, Second-line therapy or greater, Adjuvant therapy) in USA, Puerto Rico, Hungary, Poland, Spain (IV) (NCT02873819)
  • 16 Aug 2016 Gliknik plans a phase II trial for Squamous cell cancer (Adjuvant therapy, Second-line therapy or greater, Combination therapy) in USA, Czech Republic, Germany, Hungary, Poland, Spain, Serbia and Ukraine (IV) (NCT02873819)
  • 08 Aug 2016 Clinical trials in Squamous cell cancer in USA (IV) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top